Evidence map›Paper›PMID 41180007›Full record

ArticleOpen forum infectious diseases2025

Sustained HIV Suppression With Co-formulated Tenofovir Disoproxil Fumarate/Lamivudine/Dolutegravir in a Person With Transmitted Dolutegravir Resistance and Pretreatment Resistance to Lamivudine: a Case Report From HPTN 083.

Hannah P Moore, Jessica M Fogel, Mark A Marzinke, Elias K Halvas, Urvi M Parikh, John W Mellors, Kerri J Penrose, Michael Seisa, Christos Petropoulos, Amelia L Price and 10 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Open forum infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Hannah P MooreDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.ORCID https://orcid.org/0000-0001-7566-4213
Jessica M FogelDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.ORCID https://orcid.org/0000-0003-3143-9000
Mark A MarzinkeDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.ORCID https://orcid.org/0000-0003-1670-8786
Elias K HalvasDepartment of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.ORCID https://orcid.org/0000-0002-4890-1209
Urvi M ParikhDepartment of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.ORCID https://orcid.org/0000-0002-4016-0629
John W MellorsDepartment of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Kerri J PenroseDepartment of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.ORCID https://orcid.org/0000-0002-0370-5140
Michael SeisaMonogram Biosciences, South San Francisco, California, USA.
Christos PetropoulosMonogram Biosciences, South San Francisco, California, USA.
Amelia L PriceDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Amber MoserDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Zhe WangStatistical Center for HIV/AIDS Research and Prevention, Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
Marybeth McCauleyFHI 360, Durham, North Carolina, USA.
Javier Valencia-HuamaníAsociacion Civil Impacta Salud y Educacion, Lima, Peru.
Alex R RinehartViiV Healthcare, Research Triangle Park, Durham, North Carolina, USA.
James F RooneyGilead Sciences, Foster City, California, USA.ORCID https://orcid.org/0000-0003-3261-0711
Lydia Soto-TorresPrevention Science Program, Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland, USA.
Beatriz GrinsztejnInstituto de Pesquisa Clinica Evandro Chagas-Fiocruz, Rio de Janeiro, Brazil.
Raphael J LandovitzCenter for Clinical AIDS Research and Education, University of California, Los Angeles, Los Angeles, California, USA.ORCID https://orcid.org/0000-0002-1442-714X
Susan H EshlemanDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.ORCID https://orcid.org/0000-0002-4587-791X

Funding

LC: HIV Prevention Trials Network - Laboratory Support for the SARS-CoV-2 Seroprevalence Study (CoVPN 5002)UM1AI068613 · NIAID · JOHNS HOPKINS UNIVERSITY · PI SUSAN H ESHLEMAN, Mark A Marzinke · 2011 to 2026
$100.2M
Vaccine Response and Immunotherapeutics SWGP30AI094189 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Richard E. Chaisson · 2012 to 2026
$67.0M
NIAID NIH HHS P30 AI094189NIAID NIH HHS UM1 AI068613
6 · The paper itself

Abstract

Integrase strand transfer inhibitors (INSTIs) are recommended in most first-line HIV treatment regimens. We describe a participant in a clinical trial with transmitted INSTI resistance. The participant had no history of INSTI use and had no evidence of INSTI exposure prior to HIV acquisition. Treatment with tenofovir disoproxil fumarate, lamivudine (3TC), and dolutegravir (DTG) was started 3 weeks after HIV diagnosis. Viral suppression was achieved within a year and was sustained for >3 years on treatment. Retrospective HIV genotyping of a pretreatment sample detected major resistance mutations in 3 drug classes, with predicted high-level resistance to DTG and 3TC. HIV phenotyping confirmed that the transmitted virus had DTG and 3TC resistance but retained susceptibility to DTG at higher drug concentrations. Pharmacologic testing indicated that the DTG concentrations observed in this case were sufficient to overcome the effects of 2 major baseline INSTI resistance mutations (G140S and Q148H).

Indexed as

drug resistanceHIVINSTITLDtransmitted

Identifiers

PMID41180007
PMCPMC12575077

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.